The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Lessons Learned from Marketed and Investigational Prodrugs
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTLessons Learned from Marketed and Investigational ProdrugsPeter Ettmayer, Gordon L. Amidon, Bernd Clement, and Bernard TestaView Author Information Novartis Institute for BioMedical Research, Brunnerstrasse 59, A-1235 Vienna, Austria, College of Pharmacy, The University of Michigan, Ann Arbor, Michigan 48109-1065, Pharmaceutical Institute, University of Kiel, D-24118 Kiel, Germany, and Department of Pharmacy, University Hospital Centre (CHUV), CH-1011 Lausanne, Switzerland Cite this: J. Med. Chem. 2004, 47, 10, 2393–2404Publication Date (Web):April 13, 2004Publication History Received7 August 2003Published online13 April 2004Published inissue 1 May 2004https://doi.org/10.1021/jm0303812Copyright © 2004 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views6980Altmetric-Citations282LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit Read OnlinePDF (231 KB) Get e-AlertsSUBJECTS:Cells,Metabolism,Peptides and proteins,Pharmaceuticals,Targeting Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ward, A., & Clissold, S. P. (1987) · Drugs · doi:10.2165/00003495-198734010-00003 · Cited by 1,754
Encyclopedia of pharmaceutical technology
(2003) · Choice Reviews Online · doi:10.5860/choice.40-6157 · Cited by 1,743
Identification and Biological Activity of the Active Metabolite of Clopidogrel
Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., & Herbert, J. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614133 · Cited by 754
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Chemical Aspects of Selective Toxicity
ALBERT, A. (1958) · Nature · doi:10.1038/182421a0 · Cited by 401
Clarke, T. A., & Waskell, L. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.53 · Cited by 374
Beaumont, K., Webster, R., Gardner, I., & Dack, K. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489253 · Cited by 363
Bullingham, R., Monroe, S., Nicholls, A., & Hale, M. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04207.x · Cited by 318
The mechanism of action of the antisecretory agent omeprazole
Lindberg, P., Nordberg, P., Alminger, T., Braendstroem, A., & Wallmark, B. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00158a001 · Cited by 305
Han, H.-K., de Vrueh, R. L. A., Rhie, J. K., Covitz, K.-M. Y., Smith, P. L., Lee, C.-P., Oh, D.-M., Sadee, W., & Amidon1, G. L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011919319810 · Cited by 297
Self-citationReceptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Astemizole: A Review of its Pharmacodynamic Properties and Therapeutic Efficacy
Richards, D. M., Brogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1984) · Drugs · doi:10.2165/00003495-198428010-00003 · Cited by 259
Oseltamivir: A Review of its Use in Influenza
McClellan, K., & Perry, C. M. (2001) · Drugs · doi:10.2165/00003495-200161020-00011 · Cited by 257
Soft drug design: General principles and recent applications
Bodor, N., & Buchwald, P. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x · Cited by 239
Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies
Pauletti, G. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00045-8 · Cited by 233
Prodrug-activating systems in suicide gene therapy
Springer, C. J., & Niculescu-Duvaz, I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10001 · Cited by 229
Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., & Martinez, A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950475e · Cited by 223
(2001) · Wiley eBooks · doi:10.1002/9783906390437 · Cited by 212
Scientific Foundations of Oncology
Cooper, E. H. (1976) · BMJ · doi:10.1136/bmj.1.6023.1473-a · Cited by 196
Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology
Testa, B., & Mayer, J. M. (2003) · doi:10.1002/9783906390444 · Cited by 196
Self-citationA textbook of drug design and development
(1991) · European Journal of Medicinal Chemistry · doi:10.1016/0223-5234(91)90013-d · Cited by 182
Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man
Brass, E. P. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.589 · Cited by 136
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier, M. P., Sharma, S., Springer, C. J., et al. (2000) · PubMed · Cited by 128
REDUCTION OFN-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES
Clement, B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005643 · Cited by 119
Self-citationSelective Estrogen Receptor Modulators
Mitlak, B., & Cohen, F. J. (1999) · Drugs · doi:10.2165/00003495-199957050-00001 · Cited by 114
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
Giles, F. J., Estey, E. H., & O'Brien, S. M. (2003) · Cancer · doi:10.1002/cncr.11791 · Cited by 108
Pharmacological and Biochemical Actions of Sulphasalazine
Hoult, J. R. S. (1986) · Drugs · doi:10.2165/00003495-198600321-00005 · Cited by 104
New Drugs for Asthma, Allergy and COPD
Hansel, T. T., & Barnes, P. J. (2001) · Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · doi:10.1159/isbn.978-3-318-00424-3 · Cited by 95
Clement, B., & Lopian, K. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.645 · Cited by 90
Self-citationBarriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease
Bodor, N. S., & Buchwald, P. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02332-2 · Cited by 83
Biomedical Aspects of Drug Targeting
(2002) · Springer eBooks · doi:10.1007/978-1-4757-4627-3 · Cited by 80
Sievers, E. L. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.5.893 · Cited by 78
Conover, C. D., GREENWALD, R. B., Pendri, A., et al. (1999) · PubMed · Cited by 66
Prodrugs for improved CNS delivery
Anderson, B. D. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00106-h · Cited by 65
Benfield, P., & Sorkin, E. M. (1987) · Drugs · doi:10.2165/00003495-198733040-00004 · Cited by 62
Prodrugs of Peptides. 18. Synthesis and Evaluation of Various Esters of Desmopressin (dDAVP)
Kahns, A. H., Buur, A., & Bundgaard, H. (1993) · Pharmaceutical Research · doi:10.1023/a:1018973029651 · Cited by 57
Molecular Determinants of Recognition for the Intestinal Peptide Carrier
Swaan, P. W., & Tukker, J. J. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960359e · Cited by 55
Belcourt, M. F., Hodnick, W. F., Rockwell, S., & Sartorelli, A. C. (1998) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(97)00009-5 · Cited by 40
Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumor
Maeda, H. (2002) · Springer eBooks · doi:10.1007/978-1-4757-4627-3_11 · Cited by 26
Cited by
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
Prodrug strategies to overcome poor water solubility
Stella, V. J., & Nti-Addae, K. W. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.013 · Cited by 554
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475
The blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380
Metadata
- Authors
- Ettmayer, P., Amidon, G. L., Clement, B., & Testa, B.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-04-13
- Volume
- 47
- Issue
- 10
- Pages
- 2393-2404
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2951106423
- Cited by
- 384
- References
- 40
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.